← Back to Clinical Trials
Recruiting Phase 4 NCT04484675

Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension

Trial Parameters

Condition Pulmonary Hypertension Due to Left Heart Disease
Sponsor Zagazig University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 38
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-05-20
Completion 2025-05-10
Interventions
Milrinone inhalationMilrinone infusion

Brief Summary

The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery

Eligibility Criteria

Inclusion Criteria: * Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\>55 estimated by using preoperative Doppler echocardiography Exclusion Criteria: Patients were excluded if they had surgery without CPB, preoperative hemodynamic instability (defined as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease , coagulopathy, and thromboembolic disease treated with anticoagulants

Related Trials